Sirius Therapeutics Begins Phase 1 Trial for Long-Acting Factor XI siRNA Anticoagulant

04 February 2024 | Sunday | News


Sirius Therapeutics announced the administration of SRSD107 to the first subject in a Phase 1 clinical trial in Australia on January 30, 2024. SRSD107 is a next-generation siRNA therapeutic that targets clotting factor XI (FXI) and is used to prevent and treat thromboembolic disorders
Image Source : Public Domain

Image Source : Public Domain

"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events after a single subcutaneous administration," said Dr. Qunsheng Ji, Chief Executive Officer of Sirius Therapeutics. "The study will provide an opportunity to evaluate the potential of SRSD107 as a differentiated therapeutic agent for the global treatment of these common disorders."

The Phase 1 study for SRSD107, which is being conducted in healthy volunteers in Australia, is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SRSD107 at single elevated doses and multiple escalated doses.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close